Bristol Myers’ $4.1B Turning Point Buy Yields FDA Approval for Lung Cancer Drug Augtyro

The FDA has cleared Bristol Myers’ repotrectinib, to be branded as Augtyro, to treat non-small cell lung cancer patients whose tumors have ROS1 oncogenic fusions.